Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724061 · ClinicalTrials.gov registry record · NA
Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
A NA study, sponsored by Northwestern University.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00724061 is a NA study that was terminated before completion, run by Northwestern University. The registered enrollment target is 7 participants.
The verdict
NCT00724061, a NA study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of cancer cells and slow the growth of mycosis fungoides/Sezary syndrome. Ultraviolet light therapy uses a drug, such as psoralen, that is absorbed by cancer cells. The drug becomes active when it is exposed to ultraviolet light. When the drug is active, cancer cells are killed. Giving PEG-interferon alfa-2b together with ultraviolet light therapy may kill more cancer cell. PURPOSE: This is a pilot study of dose-escalating pegylated IFN-α-2b and PUVA or NB-UVB. The purpose is to study the side effects and best dose of PEG-interferon alfa-2b to be given together with ultraviolet light therapy in patients with stage IB, stage II, stage III, or stage IVA mycosis fungoides/Sezary syndrome (CTCL).
Interventions
- BIOLOGICAL Pegylated interferon α-2b
- OTHER Psoralens with ultraviolet light A
- OTHER Narrowband-ultraviolet light B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724061
The ClinicalTrials.gov registry entry for NCT00724061 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pegylated interferon α-2b is the first listed.
NCT00724061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00724061 about?
NCT00724061 is a clinical study titled "Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL". RATIONALE: PEG-interferon alfa-2b may interfere with the growth of cancer cells and slow the growth of mycosis fungoides/Sezary syndrome. Ultraviolet light therapy uses a drug, such as psoralen, that is absorbed by cancer cells. The drug becomes active when it is exposed to ultraviolet light. When t...
What is the current status of trial NCT00724061?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2008-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00724061?
The interventions under investigation include: Pegylated interferon α-2b (BIOLOGICAL), Psoralens with ultraviolet light A (OTHER), Narrowband-ultraviolet light B (OTHER).
Who is sponsoring clinical trial NCT00724061?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.